Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis

• Published in: BMC cancer Vol. 23; no. 1; pp. 1066 - 12
• Main Authors: Lu, Lanpeng, Chen, Chaohu, Cheng, Hui, Ding, Hui, Tian, Junqiang, Wang, Hanzhang, Wang, Zhiping
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.11.2023; BioMed Central; BMC
• Subjects: Adjuvant treatment; Analysis; Anemia; Antimitotic agents; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Bladder cancer; Cancer; Cancer therapies; Chemotherapy; Cisplatin; Cisplatin - therapeutic use; Clinical medicine; Confidence intervals; Cystectomy; Diseases; Gemcitabine; Health aspects; Humans; Invasiveness; Medical research; Medicine, Experimental; Meta-analysis; Missing data; Muscles; Neoadjuvant chemotherapy; Neoadjuvant Therapy - methods; Neoplasm Invasiveness; Neoplasm Recurrence, Local - drug therapy; Neutropenia; Patients; Relapse; Renal function; Retrospective Studies; Statistical analysis; Surgery; Survival; Systematic review; Thrombocytopenia; Toxicity; Urinary Bladder Neoplasms; United States; Neoadjuvant chemotherapy; Gemcitabine; Bladder cancer; Cisplatin

In muscle-invasive bladder cancer (MIBC), neoadjuvant chemotherapy (NAC) combined with radical cystectomy (RC) is critical in reducing disease recurrence, with GC (gemcitabine and cisplatin) being one of the most commonly used NACs. Different GC schedules have been used, but the best neoadjuvant reg...